Related Experiment Video
Updated: Nov 20, 2025

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic
Yasushi Iwasaki1, Keiko Mori2, Masumi Ito2
1Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University , Nagakute, Japan.
Abstract:
Methionine/methionine type 1 (MM1-type) sporadic Creutzfeldt-Jakob disease (sCJD), known as the 'classic type,' shows typical clinicopathological sCJD findings. In general, patients reach an akinetic mutism state within a few months of disease onset and die soon after if supportive therapies are not administered. Here, we describe remarkable neuropathologic observations of MM1-type sCJD in a 48-year-old, Japanese man with an unusually prolonged akinetic mutism state. In the early disease stages, the patient exhibited abnormal behaviour with gait disturbance and rapidly progressive cognitive dysfunction. Diffusion-weighted magnetic resonance imaging revealed extensive cerebral cortical hyperintensity. Prion protein (PrP) gene analysis revealed no mutations, and the polymorphic codon 129 exhibited methionine homozygosity. Although the patient remained stable with tube feeding for more than 2 years after reaching the akinetic mutism state, he died because of central respiratory failure 30 months after disease onset. Neuropathologic investigation showed extensive devastating lesions, such as status spongiosus, and typical spongiform changes could no longer be observed in the cerebral neocortex. Conspicuous pyramidal tract degeneration was observed. However, the regions commonly preserved in MM1-type sCJD pathology were still relatively preserved. Immunostaining revealed extensive diffuse synaptic-type PrP deposition in the grey matter. The pathological findings suggested that sCJD is a neurodegenerative disease that shows system degeneration; there are primary and secondary degenerative regions and distinct preserved regions, even in cases with prolonged disease duration. In addition, it is considered that there is a limited survival period for MM1-type sCJD, even if active symptomatic treatment is provided.
Insights
This study details a rare case of methionine/methionine type 1 sporadic Creutzfeldt-Jakob disease (sCJD) with an extended akinetic mutism phase. Neuropathology revealed system degeneration, highlighting distinct disease progression patterns in this classic sCJD subtype.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Sporadic Creutzfeldt-Jakob disease (sCJD) typically progresses rapidly, with methionine/methionine type 1 (MM1-type) sCJD presenting classic clinicopathological features.
- Patients with MM1-type sCJD usually reach an akinetic mutism state within months and have a poor prognosis without supportive care.
Observation:
- A 48-year-old Japanese man with MM1-type sCJD exhibited an unusually prolonged akinetic mutism state lasting over two years.
- Early symptoms included behavioral changes, gait disturbance, and rapid cognitive decline, with diffusion-weighted MRI showing extensive cerebral cortical hyperintensity.
- Prion protein (PrP) gene analysis confirmed methionine homozygosity at codon 129 without mutations.
Findings:
- Despite prolonged stability with tube feeding, the patient died 30 months post-onset due to central respiratory failure.
- Neuropathology revealed severe lesions like status spongiosus, with loss of typical spongiform changes in the neocortex but relative preservation in some areas.
- Extensive diffuse synaptic-type PrP deposition was observed in the grey matter, alongside conspicuous pyramidal tract degeneration.
Implications:
- This case underscores that sCJD involves system degeneration with primary, secondary, and preserved regions, even in prolonged cases.
- The findings suggest a limited survival period for MM1-type sCJD, irrespective of intensive symptomatic treatment.
- Understanding these distinct pathological patterns is crucial for managing and researching sCJD progression.
Related Concept Videos
Parkinson's Disease: Overview
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

